| http://www.w3.org/ns/prov#value | - Eli Lilly is withdrawing activated drotrecogin alfa (Xigris), a drug intended to treat severe sepsis in high-risk patients, from all markets including the United States as well as discontinue all ongoing clinical trials involving the drug in the wake of a new study showing that the agent did no better than a placebo in reducing mortality.
|
